Crossmark

Neoadjuvant Chemotherapy is Associated with Worse 5-Year Overall Survival in Patients with Metaplastic Breast Cancer Compared with Primary Surgery: A National Cancer Database Analysis

Crossref DOI link: https://doi.org/10.1245/s10434-025-18085-z

Published Online: 2025-08-20

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chichura, Anna M.

Chen, Xiaoying

Nelis, Margo

Kopicky, Lauren

Wei, Wei

Ali, Azka

Tendulkar, Rahul

Al-Hilli, Zahraa
License Information

Text and Data Mining valid from 2025-08-20

Version of Record valid from 2025-08-20
More Information

Article History

Received: 28 April 2025

Accepted: 29 July 2025

First Online: 20 August 2025

Disclosure

: Anna M. Chichura attended an educational course sponsored by Axogen. Lauren Kopicky is a consultant/advisory board member for Merit Medical and a Speaker for Targeted Medical Education. Azka Ali is a consultant/advisory board member for AstraZeneca, Guardant Health, and Gilead Sciences; is involved in speaking engagements and/or receives honoraria from Tersera Therapeutics, Amplity Health, MJH Life Sciences, OncLive, and Curio; and receives research funding from Symbiosis, Guardant Health, and Velosano. Rahul Tendulkar receives honoraria from Varian Medical Systems. Xiaoying Chen, Margo Nelis, Wei Wei, and Zahraa Al-Hilli have no disclosures to declare that may be relevant to the contents of this study.

Document is current

Any future updates will be listed below